Carbocysteine lysine salt - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Mucolytics and stimulators of motor function of the respiratory tract

Included in the formulation

АТХ:

R.05.C.B.03 Carbocysteine

Pharmacodynamics:Pharmacological action - mucolytic, expectorant. The activity of carbocisteine of lysine salt is due to the activation of sialic transferase - the enzyme of goblet cells of bronchial mucosa. Normalizes the proportion of acidic and neutral components of bronchial secretion, restores the viscosity and elasticity of mucus. It promotes regeneration of the mucosa, normalizes its structure, reduces the number of goblet cells, especially in the terminal bronchi and, as a consequence, reduces the production of mucus. It restores the secretion of immunologically active IgA (specific defense), improves mucociliary clearance.

Pharmacokinetics:Quickly and completely absorbed when taken orally. The maximum level in the blood serum and in the mucous membrane of the airways is reached within the first hour after ingestion, the therapeutic concentration remains in the mucous membrane for 8 hours. It undergoes biotransformation in the liver, the phenomenon of the first passage takes place. The half-life is 1.8 hours (at a dosage of 2 g / day). Complete excretion occurs after 3 days mainly with urine. Excreted unchanged in 30-60%, the rest in the form of metabolites.

Indications:- diseases accompanied by the separation of abundant and viscous sputum: tracheitis, bronchitis, tracheobronchitis, bronchial asthma, whooping cough, bronchiectasis;

- rhinitis, adenoiditis, otitis media (middle purulent otitis in children, children with secretory otitis and adults with acute inflammatory diseases of the middle ear), sinusitis;

- preparation for bronchoscopy and / or bronchography.

ICD-10

VIII.H65-H75.H66.9 Other otitis media, unspecified

VIII.H65-H75.H65.9 Pulmonary otitis media, unspecified

VIII.H65-H75.H65.3 Chronic mucosal otitis media

X.J00-J06.J00 Acute nasopharyngitis (runny nose)

X.J00-J06.J01 Acute Sinusitis

X.J00-J06.J04 Acute laryngitis and tracheitis

X.J20-J22.J20 Acute bronchitis

X.J30-J39.J31.0 Chronic rhinitis

X.J30-J39.J32 Chronic Sinusitis

X.J30-J39.J35.2 Hypertrophy of adenoids

X.J30-J39.J35.9 Chronic disease of tonsils and adenoids, unspecified

X.J30-J39.J37.1 Chronic laryngotracheitis

X.J40-J47.J42 Chronic bronchitis, unspecified

X.J40-J47.J40 Bronchitis, not specified as acute or chronic

X.J40-J47.J45 Asthma

X.J40-J47.J47 Bronchoectasia

XVIII.R00-R09.R09.3 Sputum

Contraindications:Hypersensitivity, peptic ulcer of the stomach and duodenum (in the phase of exacerbation), pregnancy (I trimester), phenylketonuria (for forms containing as a sweetener aspartame), children's age (up to 12 years - for pellets).

Carefully:Pregnancy (II-III trimesters), breast-feeding, gastric ulcer and duodenal ulcer (in the anamnesis).

Pregnancy and lactation:The FDA-B fetal action test did not reveal any risk to the fetus, and no controlled studies were conducted in pregnant women or unwanted effects (other than fertility decline) were shown in animal experiments, but their results were not confirmed in controlled studies in women in the first trimester of pregnancy (and there is no evidence of risk in other trimesters). Do not apply in the first trimester! With caution in II-III trimesters! Lactation. There is no information on the penetration into breast milk. Carefully!

Dosing and Administration:Inside.

Syrup. A dosage cup with divisions is applied to the package, according to the recommended doses. Adults: 15 ml of syrup (1.35 g) 2-3 times a day.

Granules. Adults: 1 packet per day. Dissolve the contents of the sachet in drinking water, mix, drink.

The duration of treatment (from 4 days to 6 months) is determined by the doctor. This dosage is maintained for patients with impaired liver and kidney function, as well as for patients with diabetes.

Application in elderly patients

Use in the elderly has not been systematically studied. Apply with caution taking into account contraindications.

Use in children

Decrease in viscosity of sputum. Inside. Children: older than 5 years - 5 ml of syrup (450 mg) 2-3 times a day; from 1 year to 5 years - 2.5 ml of syrup (225 mg) 2-3 times a day.

Side effects:Anaphylactoid reactions: cough, difficulty swallowing, dizziness, tachycardia, urticaria, pruritus, swelling, eyelid edema or skin around the eyes, swelling of the face, lips or tongue, shortness of breath, skin rash, pressure in the chest, unusual fatigue or weakness, sneezing, angioedema, rash, sore throat.

Bronchospastic allergic reactions, cough, allergic dermatitis, dyspnoea, face swelling, hypotension, itching, syncope.

Nausea, vomiting, stomach pain, diarrhea, gastrointestinal bleeding, dizziness, weakness, malaise.

All these disorders are transient and disappear after discontinuation of the drug or after a reduction in dosage.

Overdose:No overdoses have been reported at this time. There are side effects caused by carbocysteine: diarrhea, heartburn, nausea, vomiting, stomach pain. Treatment is symptomatic.

Interaction:Antitussives and m-holinoblokatory - weakening the effect of carbocysteine lysine salt.

Theophylline - Increased bronchodilator effect.

Special instructions:The incidence of side effects in treatment with mucolytics is comparable to placebo. In patients with diabetes it is necessary to take into account the content of sucrose in the syrup form of carbocysteine lysine salt: 5.25 g per 1 tablespoon in syrup for adults and 3.5 g for 1 teaspoon in syrup for children.

The use of carbocisteine in lysine salt does not lead to addiction or metabolic dependence.

Treatment can be combined with physiotherapy procedures.

It is not represented in the United States Pharmacopeia.

Instructions

Carbocysteine ​​Lysine Salt (Carbocisteinum lysinum)

Carbocysteine Lysine Salt (Carbocisteinum lysinum)